期刊文献+

B淋巴细胞活化因子特异的单链DNA适体的人工进化 被引量:1

Selection of single-strand DNA aptamer specifically binding to B cell activating factor
下载PDF
导出
摘要 目的:进化筛选与B淋巴细胞活化因子(B cell activating factor be longing to the TNF family,BAFF)特异结合的单链DNA适体,鉴定其结合力。方法:应用指数方式富集的配体系统进化(systemati cevolution of ligands by exponential enrich-ment,SELEX)技术,将随机序列寡核苷酸文库与BAFF分子相互作用,分离出结合的寡核苷酸配体,经反复扩增、筛选数个循环,获得重组人BAFF的单链DNA适体,应用Dot blotting鉴定其结合力,酶联法比较各适体序列对BAFF的相对结合力。结果:优化实验条件后成功进行了13轮次筛选,随机选取42个阳性克隆测序,各序列GC含量最高达75%,分为6类不同序列;Dotblotting证实这些适体均与BAFF相结合;比较各适体序列结合BAFF的光密度值,以序列44光密度值最高(0.752,P<0.05),具有对BAFF相对最高结合力。结论:首次成功获得特异结合BAFF的高亲和力的单链DNA适体,为研发防治肿瘤和自身免疫疾病新药奠定了基础。 Objective: To screen for single-strand DNA aptamers specifically binding B cell activating factor belonging to the TNF family(BAFF) and to identify its affinity. Methods: Systematic evolution of ligands by exponential enrichment (SELEX) technique was used in our study. The ssDNA ligand was separated by interaction between random oligonucleotide library and BAFF, then ssDNA aptamers binding recombinant human BAFF were obtained through PCR amplification. The binding ability of the aptamers was identified by dot blotting and the relevant affinities of each aptamer to BAFF were compared by enzyme linked aptamer assay. Results: Thirteen rounds of screening was performed under optimized condition. Six different sequences were obtained from 42 randomly-chosen positive clones, whose top GC content was up to 75%. Dot blotting confirmed that all the 6 sequences were suitable to bind with BAFF. Sequence 44 had the highest optical density in the 6 sequences in enzyme linked aptamer assay (P 〈 0.05 ), indicating it has the highest bonding force to BAF. Condusion: The ssDNA aptamers binding BAFF has been obtained for the first time, which lays a base for developing new drugs for treating autoimmune diseases and tumors.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 2007年第3期230-234,共5页 Chinese Journal of Cancer Biotherapy
基金 国家高技术研究发展(863)计划资助项目(No2006AA02Z496) 国家自然科学基金资助项目(No30471616)~~
关键词 B淋巴细胞活化因子 适体 单链DNA 指数富集的配体进化技术 进化 B cell activating factor belonging to the TNF family(BAFF) aptamer single chain DNA systematic evolution of ligands by exponential enrichment(SELEX) evolution
  • 相关文献

参考文献17

  • 1Blank M,Blind M.Aptamers as tools for target validation[J].Curr Opin Chem Biol,2005,9(4):336-342.
  • 2Hamula CL,Guthrie JW,Zhang H,et al.Selection and analytical applications of aptamers[J].Trends Anal Chem,2006,25(7):681-691.
  • 3Pestourie C,Tavitian B,Duconge F.Aptamers against extracellular targets for in vivo applications[J].Biochimie,2005,87(9-10):921-930.
  • 4Cunningham ET Jr,Adamis AP,Altaweel M,et al.A phase Ⅱ randomized double-masked trial of pegaptanib,an anti-vascular endothelial growth factor aptamer,for diabetic macular edema[J].Ophthalmology,2005,112(10):1747-1757.
  • 5Burmeister PE,Lewis SD,Silva RF,et al.Direct in vitro selection of a2'-O-methyl aptamer to VEGF[J].Chem Biol,2005,12(1):25-33.
  • 6Novak AJ,Grote DM,Stenson M,et al.Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma:correlation with disease activity and patient outcome[J].Blood,2004,104(8):2247-2253.
  • 7Ju S,Zhang D,Wang Y,et al.Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus[J].Clin Biochem,2006,39(12):1131-1137.
  • 8Endo T,Nishio M,Enzler T,et al.BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-B pathway[J].Blood,2007,109(2):703-710.
  • 9Sutherland AP,Mackay F,Mackay CR.Targeting BAFF:immunomodulation for autoimmune diseases and lymphomas[J].Pharmacol Ther,2006,112(3):774-786.
  • 10Baker KP,Edwards BM,Main SH,et al.Generation and characterization of lymphostat-B,a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator[J].ArithritisRheum,2003,48(11):3253-3265.

同被引文献24

  • 1Hicke BJ, Marion C, Chang YF, et al. Tenascin-C aptamers are generated using tumor cells and purified protein [ J ]. J Biol Chem, 2001,276 (52) : 48644 - 48654.
  • 2Daniels DA, Chen H, Hick BJ, et al. Tenascin-C aptamers identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment [ J ]. Proc Natl Acad Sci USA, 2003, 100 (26): 15416 - 15421.
  • 3Ferreira CS, Matthews CS, Missailidis S. DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1 binding single-stranded DNA aptamers [ J ]. Tumour Biol,2006,27 (26) :289 - 301.
  • 4Ferreira CS, Cheung MC, Missailidis S, et al. Phototoxie aptamers selectively enter and kill epithelial cancer cells [ J ]. Nucleic Acids Res,2009,37 (3) : 866 - 876.
  • 5Shangguan D, Cao ZC, Li Y, et al. Aptamers evolved from cultured cancer ceils reveal molecular differences of cancer ceils in patient samples [J]. J Clin Chem,2007, 53(6) :1153 - 1155.
  • 6Cerchia L, Esposito C, Jacobs A, et al. Differential SELEX in human glioma cell lines [ J/OL]. PloS One, 2009,4 ( 11 ) e7971. [2010-08-10] 10. 1371/journal. pone. 0007971.
  • 7Phillips JA, Lopez - Colon D, Zhu Z, et al. Applications of aptamers in cancer cell biology [ J ]. Anal Chim Acta,2008,621 ( 2 ) : 101 - 108.
  • 8Shi H, Tang Z, King Y, et al. In vivo fluorescence imaging of tumors molecular aptamers generated by cell- SELEX [J]. Chem Asian J,2010,5(10) :2209 -2213.
  • 9Chu TC, Marks JW, I_avery LA, et al. Aptamer: toxin conjugates that specifically target prostate tumor cells [J]. Cancer Res,2006,66(12) :5989 -5992.
  • 10Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle aptamer bioconjugates for cancer chemotherapy in vivo [ J ]. Proc Natl Acad Sci USA, 2006,103 (16) : 6315 - 6320.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部